Thermo Fisher Live Event Shorts

  1. AI In ADC Target Identification 4/29/2025

    How are AI and machine learning contributing to ADC target identification and early development? Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) tackle computational approaches to protein targets, clinical implications of target expression and internalization, and AlphaFold AI-driven pathology in this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development.

  2. ADCs & Speed To IND 4/29/2025

    In this opening segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) frame up ADC development challenges—including molecular complexity, regulatory and analytical hurdles, and strategic logistical manufacturing. We discuss those challenges in the context of the burgeoning industry’s breakneck development timelines leading up to IND submission.

  3. Outsourcing Considerations For Novel Protein Therapeutics 9/13/2024

    Panelists discuss special considerations for outsourcing the development and manufacturing of novel, complex protein therapeutics in this Bioprocess Online Live event.

  4. Addressing Aggregation And Degradation In Complex Protein Therapeutics 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss using a transient expression platform to make fast early product attribute decisions.

  5. When To Conduct Analytical Assays In Novel Protein Therapeutic Development 9/13/2024

    Panelists in the Bioprocess Online Live event discuss the various points at which analytical assays are most critical during complex protein therapeutic development.

  6. IND Prep Versus Clinical/Commercial Scale-Up In Novel Protein Therapeutics 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists share detailed considerations for scale-up of complex protein therapeutics.

  7. Addressing Post-Translational Modifications In Novel Protein Therapeutics 9/13/2024

    Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech, addresses an audience question on conjugation efficiencies in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics. From there, we move on to an audience-led discussion on when to initially address titer, PTMS, and product quality during development of novel protein therapeutic cell lines, with Lena Tholen, Ph.D, Director of Cell Line and Bioprocess Development at FyoniBio and Neeraj Pakala, Ph.D. SVP of Product Development and Manufacturing at Vera Therapeutics weighing in.

  8. Key Attributes To Monitor During Cell Line Development Of Complex Proteins 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss key attributes to monitor during cell line development processes.

  9. Cell Line Selection In Novel Protein Therapeutic Development 9/13/2024

    Lena Tholen, Ph.D., and Meinhard Hasslacher, Ph.D., weigh in early on important cell line selection considerations for novel protein therapeutics in this segment of "Early Process Considerations For Novel Protein Therapeutics".

  10. Three Novel Protein Therapeutic Worldviews 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, we meet panelists who share their topline perspectives on developing complex, novel protein therapeutics.